Egrifta (Tesamorelin Acetate) Market Report 2026
Download Free Sample Buy Now
Egrifta (Tesamorelin Acetate) Market Global Report 2026 Market Report Infographic Image

Published : February 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Egrifta (Tesamorelin Acetate) Market Report 2026

Global Outlook – By Clinical Indication (Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels), By End-Users (Hospitals, Specialized Clinics, Home Care) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Egrifta (Tesamorelin Acetate) Market Overview

• The Egrifta (Tesamorelin Acetate) market growth in the historic period has been driven by rising incidence of hiv-associated lipodystrophy, long-term antiretroviral therapy side effects

• Market expansion is supported by growth in personalized hiv care, pipeline expansion for peptide therapeutics

• Growth Driver: Rising HIV Prevalence Fuels Growth In The Egrifta (Tesamorelin Acetate) Market

• Market Trend: Resumption Of Synthetic Peptide Drug Production And Supply Management In The HIV-Related Lipodystrophy Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Egrifta (Tesamorelin Acetate) Market?

Egrifta (tesamorelin acetate) is a synthetic peptide that reduces excess abdominal fat in HIV patients with lipodystrophy by stimulating growth hormone release. It acts as a growth hormone-releasing hormone (GHRH) analog to target and decrease visceral fat. By promoting fat breakdown, it improves fat distribution and reduces health risks associated with abdominal fat.

The main clinical indications for egrifta (tesamorelin acetate) are human immunodeficiency virus (HIV)-associated lipodystrophy, growth hormone deficiency, abdominal obesity, and metabolic syndrome. HIV-associated lipodystrophy is a condition in individuals with HIV characterized by abnormal fat distribution, including fat loss from limbs and excess fat accumulation in the abdomen. It is distributed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels, and used by several end users, such as hospitals, specialized clinics, and home care.

Egrifta (Tesamorelin Acetate) Market Global Report 2026 Market Report bar graph

What Is The Egrifta (Tesamorelin Acetate) Market Size and Share 2026?

The growth in the historic period can be attributed to rising incidence of hiv-associated lipodystrophy, long-term antiretroviral therapy side effects, clinical validation of ghrh analogs, increasing awareness of visceral fat risks, unmet need for targeted abdominal fat reduction.

What Is The Egrifta (Tesamorelin Acetate) Market Growth Forecast?

The growth in the forecast period can be attributed to growth in personalized hiv care, pipeline expansion for peptide therapeutics, increasing diagnosis of metabolic complications, supportive reimbursement for specialty drugs, focus on long-term quality of life in hiv patients. Major trends in the forecast period include long-acting peptide therapies, personalized lipodystrophy treatment, expansion of metabolic indications, patient-centric injectable therapies, specialty biologic drug adoption.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Egrifta (Tesamorelin Acetate) Market Segmentation

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

What Is The Driver Of The Egrifta (Tesamorelin Acetate) Market?

The increasing prevalence of human immunodeficiency virus (HIV) cases is significantly driving the growth of the egrifta (tesamorelin acetate) market in the future. Human immunodeficiency virus (HIV) cases refer to situations where individuals are infected with HIV, gradually weakening their immune system. The rise of HIV is partly due to insufficient awareness and education about preventive measures, such as condom use and regular testing, particularly in high-risk populations. Egrifta stimulates the release of growth hormone, which helps decrease excess visceral fat and improve body composition, ultimately boosting the overall health and quality of life for individuals with HIV. For instance, in May 2024, according to the Minnesota Department of Health, a US-based state health agency, in 2023, MDH reported 324 new HIV diagnoses, marking a 24% rise from 2022. Thus, the increasing prevalence of human immunodeficiency virus (HIV) cases is driving the growth of the egrifta (tesamorelin acetate) industry.

Key Players In The Global Egrifta (Tesamorelin Acetate) Market

Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.

Global Egrifta (Tesamorelin Acetate) Market Trends and Insights

The key trend in the egrifta (tesamorelin acetate) market is focusing on developing advanced synthetic peptide drugs to enhance the effectiveness of treatments for HIV-related lipodystrophy. Synthetic peptide drugs are artificially designed compounds that aim to deliver specific therapeutic effects by mimicking or enhancing the action of naturally occurring peptides. For instance, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, announced that production of EGRIFTA SV has resumed following a voluntary shutdown of its contract manufacturer’s facility due to FDA inspection observations. A newly manufactured batch has completed quality control and will be released upon US Food and Drug Administration (FDA) approval of a prior approval supplement, and two additional batches are in production. The company is managing inventory to meet patient demand until mid-January 2025 and is working with the FDA to prevent a shortage in 2025. EGRIFTA SV is distributed only in the United States.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Egrifta (Tesamorelin Acetate) Market?

In January 2023, the World Orphan Drug Alliance (WODA), a Slovenia-based alliance of commercial distributors focused on providing access to treatments for rare diseases, announced a significant agreement with Theratechnologies for the distribution of EGRIFTA SV, a medication used to reduce excess visceral abdominal fat in adults living with HIV and lipodystrophy. This partnership aims to enhance the availability and accessibility of EGRIFTA SV, which is crucial for patients managing these conditions. Theratechnologies Inc. is a Canada-based pharmaceutical company that manufactures egrifta (tesamorelin acetate).

Regional Insights

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Egrifta (Tesamorelin Acetate) Market?

The egrifta (tesamorelin acetate) market consists of sales of tesamorelin acetate injections and tesamorelin acetate vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Egrifta (Tesamorelin Acetate) Market Report 2026?

The egrifta (tesamorelin acetate) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the egrifta (tesamorelin acetate) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Egrifta (Tesamorelin Acetate) Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $ billion
Revenue Forecast In 2035 $ billion
Growth Rate No CAGR found from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Clinical Indication, Distribution Channel, End-Users
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Theratechnologies Inc.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Egrifta (Tesamorelin Acetate) Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Egrifta (Tesamorelin Acetate) Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Egrifta (Tesamorelin Acetate) Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Egrifta (Tesamorelin Acetate) Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Long-Acting Peptide Therapies

4.2.2 Personalized Lipodystrophy Treatment

4.2.3 Expansion Of Metabolic Indications

4.2.4 Patient-Centric Injectable Therapies

4.2.5 Specialty Biologic Drug Adoption

5. Egrifta (Tesamorelin Acetate) Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialized HIV Clinics

5.3 Endocrinology Clinics

5.4 Ambulatory Care Centers

5.5 Home Care Settings

6. Egrifta (Tesamorelin Acetate) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Egrifta (Tesamorelin Acetate) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Egrifta (Tesamorelin Acetate) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Egrifta (Tesamorelin Acetate) Market Size, Comparisons And Growth Rate Analysis

7.3. Global Egrifta (Tesamorelin Acetate) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Egrifta (Tesamorelin Acetate) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Egrifta (Tesamorelin Acetate) Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Egrifta (Tesamorelin Acetate) Market Segmentation

9.1. Global Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

9.2. Global Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

9.3. Global Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialized Clinics, Home Care

10. Egrifta (Tesamorelin Acetate) Market Regional And Country Analysis

10.1. Global Egrifta (Tesamorelin Acetate) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Egrifta (Tesamorelin Acetate) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Egrifta (Tesamorelin Acetate) Market

11.1. Asia-Pacific Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Egrifta (Tesamorelin Acetate) Market

12.1. China Egrifta (Tesamorelin Acetate) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Egrifta (Tesamorelin Acetate) Market

13.1. India Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Egrifta (Tesamorelin Acetate) Market

14.1. Japan Egrifta (Tesamorelin Acetate) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Egrifta (Tesamorelin Acetate) Market

15.1. Australia Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Egrifta (Tesamorelin Acetate) Market

16.1. South Korea Egrifta (Tesamorelin Acetate) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

16.2. South Korea Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Egrifta (Tesamorelin Acetate) Market

17.1. Western Europe Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. Western Europe Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Egrifta (Tesamorelin Acetate) Market

18.1. UK Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Egrifta (Tesamorelin Acetate) Market

19.1. Germany Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Egrifta (Tesamorelin Acetate) Market

20.1. France Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Egrifta (Tesamorelin Acetate) Market

21.1. Eastern Europe Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

21.2. Eastern Europe Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Egrifta (Tesamorelin Acetate) Market

22.1. North America Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

22.2. North America Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Egrifta (Tesamorelin Acetate) Market

23.1. USA Egrifta (Tesamorelin Acetate) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

23.2. USA Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Egrifta (Tesamorelin Acetate) Market

24.1. Canada Egrifta (Tesamorelin Acetate) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

24.2. Canada Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Egrifta (Tesamorelin Acetate) Market

25.1. South America Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

25.2. South America Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Egrifta (Tesamorelin Acetate) Market

26.1. Middle East Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Middle East Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Egrifta (Tesamorelin Acetate) Market

27.1. Africa Egrifta (Tesamorelin Acetate) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

27.2. Africa Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Egrifta (Tesamorelin Acetate) Market Regulatory and Investment Landscape

29. Egrifta (Tesamorelin Acetate) Market Competitive Landscape And Company Profiles

29.1. Egrifta (Tesamorelin Acetate) Market Competitive Landscape And Market Share 2024

29.1.1. Top 10 Companies (Ranked by revenue/share)

29.2. Egrifta (Tesamorelin Acetate) Market - Company Scoring Matrix

29.2.1. Market Revenues

29.2.2. Product Innovation Score

29.2.3. Brand Recognition

29.3. Egrifta (Tesamorelin Acetate) Market Company Profiles

29.3.1. Theratechnologies Inc. Overview, Products and Services, Strategy and Financial Analysis

30. Global Egrifta (Tesamorelin Acetate) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Egrifta (Tesamorelin Acetate) Market

32. Egrifta (Tesamorelin Acetate) Market High Potential Countries, Segments and Strategies

32.1 Egrifta (Tesamorelin Acetate) Market In 2030 - Countries Offering Most New Opportunities

32.2 Egrifta (Tesamorelin Acetate) Market In 2030 - Segments Offering Most New Opportunities

32.3 Egrifta (Tesamorelin Acetate) Market In 2030 - Growth Strategies

32.3.1 Market Trend Based Strategies

32.3.2 Competitor Strategies

33. Appendix

33.1. Abbreviations

33.2. Currencies

33.3. Historic And Forecast Inflation Rates

33.4. Research Inquiries

33.5. The Business Research Company

33.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Egrifta (Tesamorelin Acetate) Market, Overview Of Key Products - Product Examples
  • Table 2: Global Egrifta (Tesamorelin Acetate) Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Egrifta (Tesamorelin Acetate) Market, Supply Chain Analysis
  • Table 4: Global Egrifta (Tesamorelin Acetate) Market, Major Raw Material Providers
  • Table 5: Global Egrifta (Tesamorelin Acetate) Market, Major Resource Providers
  • Table 6: Global Egrifta (Tesamorelin Acetate) Market, Major Manufacturers (Suppliers)
  • Table 7: Global Egrifta (Tesamorelin Acetate) Market, Major Distributors And Channel Partners
  • Table 8: Global Egrifta (Tesamorelin Acetate) Market, Key Technologies & Future Trends
  • Table 9: Global Egrifta (Tesamorelin Acetate) Market, Major Trends
  • Table 10: Global Egrifta (Tesamorelin Acetate) Market, Major End Users
  • Table 11: Global Egrifta (Tesamorelin Acetate) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Egrifta (Tesamorelin Acetate) Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Egrifta (Tesamorelin Acetate) Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Egrifta (Tesamorelin Acetate) Market - TAM, US$ Billion, 2025
  • Table 15: Global Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Egrifta (Tesamorelin Acetate) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Egrifta (Tesamorelin Acetate) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Asia-Pacific, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Asia-Pacific, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Asia-Pacific, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: China, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: China, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: China, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: India, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: India, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: India, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: Japan, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: Japan, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: Japan, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: Australia, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Australia, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Australia, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: South Korea, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: South Korea, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: South Korea, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Western Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Western Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Western Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: UK, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: UK, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: UK, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: Germany, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Germany, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Germany, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: France, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: France, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: France, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: Eastern Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Eastern Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Eastern Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: North America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: North America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: North America, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: USA, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: USA, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: USA, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Canada, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Canada, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Canada, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: South America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: South America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: South America, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Middle East, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Middle East, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Middle East, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Africa, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Africa, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Africa, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Global Egrifta (Tesamorelin Acetate) Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 72: Global Egrifta (Tesamorelin Acetate) Market - Company Scoring Matrix
  • Table 73: Theratechnologies Inc. Financial Performance
  • Table 74: Global Egrifta (Tesamorelin Acetate) Market, Competitive Benchmarking (In USD Billions)
  • Table 75: Global Egrifta (Tesamorelin Acetate) Market, Competitive Dashboard
  • Table 76: Global Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 77: Global, Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), Segmentation By Clinical Indication, 2025 – 2030
  • Table 78: Global, Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Table 79: Global, Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), Segmentation By End-Users, 2025 – 2030

List Of Figures

    Figure 1: Global Egrifta (Tesamorelin Acetate) Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Egrifta (Tesamorelin Acetate) Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Egrifta (Tesamorelin Acetate) Market, Supply Chain Analysis
  • Figure 4: Global Egrifta (Tesamorelin Acetate) Market, Major Raw Material Providers
  • Figure 5: Global Egrifta (Tesamorelin Acetate) Market, Major Resource Providers
  • Figure 6: Global Egrifta (Tesamorelin Acetate) Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Egrifta (Tesamorelin Acetate) Market, Major Distributors And Channel Partners
  • Figure 8: Global Egrifta (Tesamorelin Acetate) Market, Key Technologies & Future Trends
  • Figure 9: Global Egrifta (Tesamorelin Acetate) Market, Major Trends
  • Figure 10: Global Egrifta (Tesamorelin Acetate) Market, Major End Users
  • Figure 11: Global Egrifta (Tesamorelin Acetate) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Egrifta (Tesamorelin Acetate) Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Egrifta (Tesamorelin Acetate) Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Egrifta (Tesamorelin Acetate) Market - TAM, US$ Billion, 2025
  • Figure 15: Global Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Egrifta (Tesamorelin Acetate) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Egrifta (Tesamorelin Acetate) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Asia-Pacific, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Asia-Pacific, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Asia-Pacific, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: China, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: China, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: China, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: India, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: India, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: India, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: Japan, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: Japan, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: Japan, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: Australia, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Australia, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Australia, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: South Korea, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: South Korea, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: South Korea, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Western Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Western Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Western Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: UK, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: UK, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: UK, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: Germany, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Germany, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Germany, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: France, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: France, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: France, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: Eastern Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Eastern Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Eastern Europe, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: North America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: North America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: North America, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: USA, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: USA, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: USA, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Canada, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Canada, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Canada, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: South America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: South America, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: South America, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Middle East, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Middle East, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Middle East, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Africa, Egrifta (Tesamorelin Acetate) Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Africa, Egrifta (Tesamorelin Acetate) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Africa, Egrifta (Tesamorelin Acetate) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Global Egrifta (Tesamorelin Acetate) Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 72: Global Egrifta (Tesamorelin Acetate) Market - Company Scoring Matrix
  • Figure 73: Theratechnologies Inc. Financial Performance
  • Figure 74: Global Egrifta (Tesamorelin Acetate) Market, Competitive Benchmarking (In USD Billions)
  • Figure 75: Global Egrifta (Tesamorelin Acetate) Market, Competitive Dashboard
  • Figure 76: Global Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 77: Global, Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), Segmentation By Clinical Indication, 2025 – 2030
  • Figure 78: Global, Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Figure 79: Global, Egrifta (Tesamorelin Acetate) Market Size Gain ($ Billion), Segmentation By End-Users, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Read More About CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Read More About Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Read More About Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Ho...

Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

Anti-Infective Drugs Global Market Report 2022 – By Type (Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others...

Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Dru...

Dermatology Drugs Global Market Report 2022 – By Type (Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By R...

Frequently Asked Questions

The Egrifta (Tesamorelin Acetate) market was valued at $ billion in 2025, increased to $ billion in 2026, and is projected to reach $ billion by 2030.

The global Egrifta (Tesamorelin Acetate) market is expected to grow at a CAGR of nan% from 2026 to 2035 to reach $ billion by 2035.

Some Key Players in the Egrifta (Tesamorelin Acetate) market Include, Theratechnologies Inc. .

Major trend in this market includes: Resumption Of Synthetic Peptide Drug Production And Supply Management In The HIV-Related Lipodystrophy Market. For further insights on this market. request a sample here

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us